✦ LIBER ✦

Dose escalation of gemcitabine concomitant with radiation and cisplatin for nonsmall cell lung cancer : A phase 1-2 study

✍ Scribed by Felix Momm; Markus Kaden; Ian Tannock; Martin Schumacher; Joachim Hasse; Michael Henke

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 149 KB
Volume: 116
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25366

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Toxicity report of a phase 1/2 dose-esca

Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy

✍ Samuel Bral; Michaël Duchateau; Harijati Versmessen; Douwe Verdries; Benedikt En 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB

Biomarker-based phase I dose-escalation,

Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer

✍ Karen Reckamp; Barbara Gitlitz; Lin-Chi Chen; Ravi Patel; Ginger Milne; Mary Syt 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 1 views

Phase 2 study of high-dose proton therap

Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer

✍ Joe Y. Chang; Ritsuko Komaki; Charles Lu; Hong Y. Wen; Pamela K. Allen; Anne Tsa 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 2 views

Irinotecan and cisplatin with concurrent

Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer : A multiinstitutional phase 2 study

✍ Minoru Fukuda; Hiroshi Soda; Masaaki Fukuda; Akitoshi Kinoshita; Yoichi Nakamura 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 1 views

## Abstract ## BACKGROUND. The purpose was to determine the efficacy and toxicity of irinotecan and cisplatin with concurrent split‐course thoracic radiotherapy (TRT) in locally advanced nonsmall‐cell lung cancer. ## METHODS. Fifty patients fulfilling the following eligibility criteria were enro

Gemcitabine, paclitaxel, and cisplatin a

Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven Stage IIIA(N2) nonsmall cell lung carcinoma : A phase II multicenter study

✍ Filippo De Marinis; Fabrizio Nelli; Maria Rita Migliorino; Olga Martelli; Enrico 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB

## Abstract ## BACKGROUND The objective of the current study was to define the activity and tolerability, as well as the influence on resectability, of the combination of gemcitabine, paclitaxel, and cisplatin (GTP) as induction chemotherapy for patients with Stage IIIA(N2) nonsmall cell lung carc

Gemcitabine and cisplatin as induction c

Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma : An Italian Lung Cancer Project Observational Study

✍ Federico Cappuzzo; Giovanni Selvaggi; Vanesa Gregorc; Francesca Mazzoni; Maura B 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

## Abstract ## BACKGROUND The objective of this trial was to evaluate the activity and safety of one of the newer platinum‐based doublets as a neoadjuvant regimen in patients with unresectable Stage IIIA‐bulky N2 and Stage IIIB nonsmall cell lung carcinoma (NSCLC). ## METHODS From June 1996 to A